MariMed Inc. (MRMD) Q4 2025 Earnings Call Transcript

SA Transcripts158.94K FollowersFollow5ShareSaveCommentsQ4: 2026-03-11 Earnings SummaryInsightsTranscript InsightsPlay CallPlay CallEPS of $0.01 beats by $0.02 | Revenue of $41.65M (6.79% Y/Y) beats by $850.00K MariMed Inc. (MRMD) Q4 2025 Earnings Call March 12, 2026 8:00 AM EDT Company Participants Andrew PachecoJon Levine - Co-Founder, CEO, President, Secretary, Treasurer & DirectorRyan Crandall - Chief Commercial OfficerMario Pinho - Chief Financial Officer Conference Call Participants Pablo Zuanic - Zuanic & AssociatesJoseph Gomes - NOBLE Capital Markets, Inc., Research Division Presentation Operator Thank you for standing by. At this time, I would like to welcome everyone to the MariMed Fiscal Year and Fourth Quarter 2025 Earnings Call. [Operator Instructions] I would now like to turn the conference over to Andrew Pacheco, General Manager for MariMed in Massachusetts. Sir, the floor is yours.

Andrew Pacheco Hello, and good morning, everyone. I'm Andrew Pacheco, General Manager for Massachusetts at MariMed. I'm honored to kick off today's 2025 fiscal year and fourth quarter earnings call. My team at our New Bedford cultivation and processing facility is responsible for the manufacturing of our great brands that is distributed throughout the state. I'm privileged to see firsthand the expertise, collaboration and dedication our employees contribute on a daily basis. They take the company's mission to improve lives every day very seriously. You're going to hear during this call about our performance in Massachusetts in 2025 relative to the rest of the market. And I think it's our team's commitment to our success that's a huge part of what differentiates us and our performance in Massachusetts. Joining the call today are Jon Levine, our Chief Executive Officer; Ryan Crandall, our Chief Commercial Officer; and Mario Pinho, our Chief Financial Officer. This call will be archived on our Investor Relations website and contains forward-looking statements. Actual events or results may differ materially from these forward-looking statements and are subject to various risks and uncertainties. These risks are discussed in the Risk Factors section